Assertio Holdings, Inc. (ASRT)
12.00
-0.04
(-0.29%)
USD |
NASDAQ |
Feb 24, 16:00
12.00
0.00 (0.00%)
After-Hours: 20:00
Assertio Holdings Research and Development Expense (Quarterly) : 0.379M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alkermes Plc | 80.34M |
| Altimmune, Inc. | 14.93M |
| Verastem, Inc. | 28.99M |
| Actinium Pharmaceuticals, Inc. | 4.042M |
| Ultragenyx Pharmaceutical, Inc. | 194.22M |